Antwi-Amoabeng Daniel, Sathappan Sunil, Beutler Bryce D, Ulanja Mark B, Awad Munadel, Gullapalli Nageshwara, Duncan Phillip, Gbadebo T David
Department of Internal Medicine, Reno School of Medicine, University of Nevada, Reno, NV 89502, USA.
Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Clin Pract. 2022 Jul 15;12(4):557-564. doi: 10.3390/clinpract12040059.
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.
恩格列净是一种钠-葡萄糖协同转运蛋白2抑制剂，已被证明可与小鼠心肌细胞中的晚钠通道结合。我们试图研究糖尿病患者使用恩格列净相关的心电图（ECG）特征。我们比较了101例患者在开始使用恩格列净前后的心电图特征，发现恩格列净与心力衰竭糖尿病患者的QRS波时限显著增加有关。
